Dive into the archives.
- Newly Published Data Show Copaxone Promoted Remyelination of Damaged Axons
The purpose of this study was to examine the effect of glatiramer acetate on oligodendrogenesis (the formation of myelin-producing glial cells in the central nervous system) and myelin formation in damaged nerve cells in mice
The mice were subjected to lysolecithin-induced demyelination of the spinal cord, then treated daily for seven days with a 2mg injection [...]
- Copaxone Used for First-Episode/CIS Halves MS Risk
PARIS — Early treatment with a key drug to fight multiple sclerosis (MS) nearly halves the risk of progression to the full-blown disease, according to a study published online on Wednesday by The Lancet.
The treatment, glatiramer acetate, marketed as Copaxone, was tested in 16 countries among 481 patients with a telltale lesion in the central [...]
- Hot off the ECTRIMS Press…Fewer Injection Site Reactions with Avonex
CAMBRIDGE, MA – Sept. 11, 2009 – Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon (interferon beta-1b), Copaxone (glatiramer Acetate) or Rebif (interferon beta-1a). [...]
- NIH Deepens Investment In Avonex and Copaxone Combination Study
Article Date: 22 Jul 2009 – 4:00 PDT
The first large-scale “CombiRX” clinical trial testing the combined use of FDA-approved interferon beta-1a (Avonex®) and glatiramer acetate (Copaxone®) to treat relapsing-remitting MS has just received a $19-million renewal grant from the National Institutes of Health. This is the largest MS trial ever supported by the [...]
- Hot off the AAN Press: Study Suggests Copaxone has Protective Effects
Long-Term Study with COPAXONE® Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
- New Data Presented at 61st Annual Meeting of the American Academy of Neurology -
JERUSALEM–New data presented today provided evidence that long-term treatment with COPAXONE® (glatiramer acetate injection) [...]
- Copaxone FDA approved for First Episode (CIS, for you seasoned readers)
COPAXONE(R) Approved By The FDA For Patients With A First Clinical Event Suggestive Of Multiple Sclerosis
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for COPAXONE® (glatiramer acetate injection) to include the treatment of patients who have experienced a first clinical episode and [...]
